Clinical Trial: Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)

U.S., April 7 -- ClinicalTrials.gov registry received information related to the study (NCT07513181) titled 'Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)' on April 01.

Brief Summary: The primary objective of this trial is to evaluate the clinical efficacy of ATH-063 in participants with biologic/advanced therapy relapsed/refractory moderately to severely active UC.

Study Start Date: May, 2026

Study Type: INTERVENTIONAL

Condition: Ulcerative Colitis Inflammatory Bowel Diseases Autoimmune Diseases

Intervention: DRUG: ATH-063

Three 50 mg capsules, total dose 150 mg.

OTHER: Placebo

Identical capsule to the drug ...